{
    "organizations": [],
    "uuid": "6d623a73ded3428fe6b9dd63ab80c89195e8f118",
    "author": "",
    "url": "https://www.reuters.com/article/brief-protalix-biotherapeutics-reports-p/brief-protalix-biotherapeutics-reports-positive-interim-data-from-phase-ii-clinical-trial-of-oprx-106-idUSASB0BZEC",
    "ord_in_thread": 0,
    "title": "BRIEF-Protalix Biotherapeutics Reports Positive Interim Data From Phase II Clinical Trial Of Oprx-106",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 12 PM / Updated 10 minutes ago BRIEF-Protalix Biotherapeutics Reports Positive Interim Data From Phase II Clinical Trial Of Oprx-106 Reuters Staff 1 Min Read \nJan 2 (Reuters) - Protalix Biotherapeutics Inc: \n* PROTALIX BIOTHERAPEUTICS REPORTS POSITIVE INTERIM DATA FROM PHASE II CLINICAL TRIAL OF OPRX-106 IN PATIENTS WITH ULCERATIVE COLITIS \n* PROTALIX BIOTHERAPEUTICS - ‍TREATMENT WAS WELL TOLERATED AND MAJORITY OF ADVERSE EVENTS HAVE BEEN MILD TO MODERATE AND TRANSIENT IN NATURE IN STUDY​ \n* PROTALIX BIOTHERAPEUTICS - EXPECTS TO REPORT FULL RESULTS FROM PHASE II CLINICAL TRIAL OF OPRX-106 BY END OF Q1 2018  ",
    "published": "2018-01-02T14:11:00.000+02:00",
    "crawled": "2018-01-02T14:32:26.031+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "biotherapeutics",
        "report",
        "positive",
        "interim",
        "data",
        "phase",
        "ii",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "protalix",
        "biotherapeutics",
        "inc",
        "protalix",
        "biotherapeutics",
        "report",
        "positive",
        "interim",
        "data",
        "phase",
        "ii",
        "clinical",
        "trial",
        "patient",
        "ulcerative",
        "colitis",
        "protalix",
        "biotherapeutics",
        "well",
        "tolerated",
        "majority",
        "adverse",
        "event",
        "mild",
        "moderate",
        "transient",
        "nature",
        "protalix",
        "biotherapeutics",
        "expects",
        "report",
        "full",
        "result",
        "phase",
        "ii",
        "clinical",
        "trial",
        "end",
        "q1"
    ]
}